Targeted therapies, such as EGFR tyrosine kinase inhibitors (TKIs), have been successfully implemented for the treatment of NSCLC in patients with advanced or metastatic NSCLC carrying EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.